Montelukast Accord

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients who require maintenance therapy. GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma (maintenance therapy): reduces frequency of symptoms and need for rescue medication in patients with persistent asthma. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity, improving exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness - Fatigue - Cough

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Mood changes, including depression or suicidal thoughts - Hepatic enzyme elevation - Stevens‑Johnson syndrome or other severe skin reactions

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control before initiating: ensure patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric symptoms: report any mood changes or suicidal thoughts promptly. - Avoid use in patients with known hypersensitivity to montelukast or its excipients. - Use with caution in hepatic impairment: consider dose adjustment or close monitoring. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations. - Phenobarbital: may markedly reduce montelukast effectiveness. - Carbamazepine: can lower montelukast exposure, diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast levels; monitor for side effects. - Warfarin: potential interaction; observe INR and adjust anticoagulant dose if needed.